Labeled for this condition
Medicines for hepatitis c
8 medicines have an FDA label indicated for hepatitis c; 1 are listed from generic labelers and 0 have a presentation in shortage now (FDA files, October 8, 2026).
Which medicines are labeled for hepatitis c?
Each label names the condition in its indications; the record shows the label's words. A list of labeled medicines is not a treatment plan.
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Ribavirin | none listed | 1 labeler | $0.451 per tablet 200 mg tablet | Yes | No current entry | 0 |
| Ledipasvir and sofosbuvir | Harvoni | none listed | n/a | Yes | No current entry | 0 |
| Sofosbuvir and velpatasvir | Epclusa | none listed | $278.03 per unit 400-100 | Yes | No current entry | 1 |
| Sofosbuvir | Sovaldi | none listed | n/a | Yes | No current entry | 0 |
| Glecaprevir and pibrentasvir | Mavyret | none listed | $152.98 per tablet 100-40 mg tablet | Yes | No current entry | 0 |
| Peginterferon alfa 2a | Pegasys | none listed | n/a | Yes | Resolved | 0 |
| Elbasvir and grazoprevir | Zepatier | none listed | n/a | Yes | A presentation being discontinued | 0 |
| Sofosbuvir and velpatasvir and voxilaprevir | Vosevi | none listed | n/a | Yes | No current entry | 0 |
Source: FDA drug labels (indications) via openFDA; NDC Directory; CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price